Champions Oncology Inc
F:2I3
Operating Margin
Champions Oncology Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Champions Oncology Inc
NASDAQ:CSBR
|
113.6m USD |
11%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
15%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
150.2B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
140.5B USD |
22%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
32%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.1B CHF |
18%
|
|
| JP |
D
|
DNA Chip Research Inc
TSE:2397
|
6.8T JPY |
4%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.8B USD |
23%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD |
15%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
188.5B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24B USD |
29%
|
Champions Oncology Inc
Glance View
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Champions Oncology Inc's most recent financial statements, the company has Operating Margin of 10.7%.
You don't have any saved screeners yet